MX1 and leukemia: Also, NrasG12D/G12D; Mx1‐Cre+; Golga7HET mice had prolonged OS (median, 124 days; P = 0.0061) when compared to Golga7WT counterparts, suggesting a moderate dose‐dependent inhibitory effect of Golga7 loss on NrasG12D‐driven leukemia development (Figure 1D).